Hematology

For information on the following Clinical Trials, please contact the
Hematology, Oncology and Stem Cell Transplantation Department
at 773-880-4562 during 8:30 AM to 5:00 PM Central Standard Time.

Hemophilia Investigator
Factor XIII Fibrogammin P  Alexis Thompson, MD
Genetics of Inhibitor in Siblings with Hmophilia   Alexis Thompson, MD
Recombinant Human Factor IX (rFIX) for Treatment of Hemophilia B Alexis Thompson, MD
Universal Data Collection (UDC)  Alexis Thompson, MD
Hemophilia and Thrombosis Research Society Registry (HTRS) Alexis Thompson, MD
Hemophilic Genotype, Inhibitors and Response to Immune Tolerance Alexis Thompson, MD
Risk Factors for Inhibitor Development in Mild or Moderate Hemophilia A Alexis Thompson, MD
Response to DDAVP in Children with Type 1 Von Willebrand Disease Using the PFA-100 Alexis Thompson, MD
   

Sickle Cell

 Investigator
Attitudes Toward Scholastic Achievement among Adolescents with Sickle Cell Anemia and Their Caregivers: A Needs Attitudes Assessment Project Robert Liem, MD
Chronic ImmuneThrombocytopenic Purpura Registry Alexis Thompson, MD

Evaluation of Free-Living Physical Activity and Its Relationship to Exercise Capacity in Children and Adolescents with Sickle Cell Anemia

 Robert Liem, MD
Improve (Improving Pain Management and Outcomes)  Kyle Mack, MD
Novartis 2411 Registry Trial Alexis Thompson, MD
Novartis 109E - Long-term Treatment with ICL Alexis Thompson, MD
Novartis US19 - T2 Star Alexis Thompson, MD
Novartis US 2209  Alexis Thompson, MD
Novartis US 32  Alexis Thompson, MD
Proactive (Preventing Acute Chest Syndrome)  Alexis Thompson, MD
Pulmonary Hypertension Prevalence Study (PHT) Robert Liem, MD
Pulmonary Hypertension-Hydroxyurea Pilot Trial (PHT-HU) Robert Liem, MD
Silent Infarct Transfusion Trial in Sickle Cell Patients (SITT)  Alexis Thompson, MD
sPLA2 Inhibitor in Sickle Cell Patients Alexis Thompson, MD
Sickle Cell Patients w Stroke and Transfusions Changing to Hydroxyurea (SWiTCH) Alexis Thompson, MD
Genetic Basis of Variability of Opioid Resp. in Ped Adoles Patients w/SCD A. Kyle Mack, MD
The Physiologic Assessment of Exercise Capacity in Pediatric Sickle Cell Anemia Robert Liem, MD
Tricuspid Regurgitant Jet Velocity in Children and Young Adults with Sickle Cell Disease Robert Liem, MD
The Clinical Pharmacology of Hydroxyurea in Pediatric Patient's with Sickle Cell Disease Robert Liem, MD
Warfarin Pharmacogenetics in Pediatric Patients Alexis Thompson, MD
   
Thalassemia Investigator
Novartis US04 - Evaluating Cardiac T2 Star in Beta Thalassemia Patients on ICL Alexis Thompson, MD
Rand. Trial Comparing DFO and L1 Effects on Cardiac Func in B Thal Adult Pts Alexis Thompson, MD
Sociocultural Barriers to Healthcare Access in Asian and Asian Indian Families Affected byThalassemia: A Qualitative Study         Robert Liem, MD
TCRN- Assessment of Pain Survey  Alexis Thompson, MD
Thalassemia Data Collection (CDC) Alexis Thompson, MD
Thalassemia Longitudinal Cohort (TLC) Alexis Thompson, MD

Back to the top of the page